The author would like to correct the following error in the online publication of the article.
In page 233, under the second paragraph of ''Limitation'' section, the following sentence has not to be considered: ''An additional limitation is related to the differences in labelling of the two studied drugs: rasagiline is indicated also as monotherapy, whereas selegiline only as add-on therapy. This difference could have influenced our results.'' because both these drugs are authorized by Italian Medicines Agency (AIFA) either as monotherapy or in combination in patients with Parkinson's disease.
